Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -381.53% is 51% below its 5-year average of -253.27%, near the low end of its 5-year range (-499.84%–-53.85%).
15.48% below its 12-month average of -330.40%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -78.06%.
RETURN ON ASSETS (ROA)
-381.53%
RETURN ON ASSETS (ROA) AVG TTM
-330.40%
RETURN ON ASSETS (ROA) AVG 3Y
-209.86%
RETURN ON ASSETS (ROA) AVG 5Y
-253.27%
RETURN ON ASSETS (ROA) AVG 10Y
-1184.24%
RETURN ON ASSETS (ROA) AVG 15Y
-950.61%
RETURN ON ASSETS (ROA) AVG 20Y
-747.81%
CURRENT VS TTM AVG
-15.48%
CURRENT VS 3Y AVG
-81.80%
CURRENT VS 5Y AVG
-50.64%
CURRENT VS 10Y AVG
+67.78%
CURRENT VS 15Y AVG
+59.86%
CURRENT VS 20Y AVG
+48.98%
SECTOR MEDIAN · HEALTHCARE
-31.77%
median of 814 covered companies
CURRENT VS SECTOR MEDIAN
-1100.91%
vs the sector median at left
GT Biopharma, Inc.
Market Cap
$7.95M
Return on Assets (ROA)
-381.53%
TTM Avg
-330.40%
3Y Avg
-209.86%
5Y Avg
-253.27%
Market Cap
$8.01M
Return on Assets (ROA)
-76.12%
TTM Avg
-177.28%
3Y Avg
-394.98%
5Y Avg
-300.85%
Market Cap
$7.93M
Return on Assets (ROA)
86.37%
TTM Avg
-66.33%
3Y Avg
-66.09%
5Y Avg
-69.89%
Market Cap
$8.13M
Return on Assets (ROA)
-29.10%
TTM Avg
-66.56%
3Y Avg
-142.45%
5Y Avg
-115.37%
Market Cap
$7.81M
Return on Assets (ROA)
-74.50%
TTM Avg
-220.41%
3Y Avg
-182.97%
5Y Avg
-158.82%
Market Cap
$8.18M
Return on Assets (ROA)
N/A
TTM Avg
-103.86%
3Y Avg
-117.64%
5Y Avg
-138.14%
Market Cap
$8.36M
Return on Assets (ROA)
-23.11%
TTM Avg
-173.03%
3Y Avg
-145.25%
5Y Avg
-97.33%
Market Cap
$7.43M
Return on Assets (ROA)
-74.58%
TTM Avg
-69.72%
3Y Avg
-51.64%
5Y Avg
-52.44%
Market Cap
$8.53M
Return on Assets (ROA)
-269.47%
TTM Avg
-172.22%
3Y Avg
-300.06%
5Y Avg
-300.06%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | $7.95M | -381.53% | -330.40% | -209.86% | -253.27% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $8.01M | -76.12% | -177.28% | -394.98% | -300.85% |
| Traws Pharma, Inc. (TRAW)vs › | $7.93M | 86.37% | -66.33% | -66.09% | -69.89% |
| Aprea Therapeutics, Inc. (APRE)vs › | $8.13M | -29.10% | -66.56% | -142.45% | -115.37% |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.81M | -74.50% | -220.41% | -182.97% | -158.82% |
| HeartSciences Inc. (HSCS)vs › | $8.18M | N/A | -103.86% | -117.64% | -138.14% |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.36M | -23.11% | -173.03% | -145.25% | -97.33% |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.43M | -74.58% | -69.72% | -51.64% | -52.44% |
| DataMEDS AI, Inc. (MEDS)vs › | $8.53M | -269.47% | -172.22% | -300.06% | -300.06% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.31M | -457.62% | -117.02% | -190.78% | -182.53% |
ROA
-381.5%
ROE
-618.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -349.79% |
| 2024-12-31 | -311.01% |
| 2023-12-31 | -53.85% |
| 2022-12-31 | -124.78% |
| 2021-12-31 | -180.34% |
| 2020-12-31 | -499.84% |
| 2019-12-31 | -9759.34% |
| 2018-12-31 | -1020.46% |
| 2017-12-31 | -56.68% |
| 2016-12-31 | 39072.00% |
| 2015-12-31 | -39742.59% |
| 2014-12-31 | -2645.16% |
| 2013-12-31 | -340.82% |
| 2012-12-31 | -2288.05% |
| 2011-12-31 | -2868.22% |
| 2010-12-31 | -1618.92% |
| 2009-12-31 | -162.28% |
| 2008-12-31 | -848.47% |
| 2007-12-31 | 9.70% |
| 2006-12-31 | -61.77% |
| 2005-12-31 | -39.83% |
| 2004-12-31 | -31.83% |
| 2003-12-31 | -40.30% |
| 2002-12-31 | -41.41% |
| 2001-12-31 | -203.08% |
| 2000-12-31 | -83.27% |
| 1999-12-31 | -86.71% |
| 1998-12-31 | -63.39% |
| 1997-12-31 | -41.27% |
| 1996-12-31 | -75.00% |
